Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 16 or older at the time of signing the consent form.
- People who have been formally diagnosed with systemic lupus erythematosus (SLE) — a chronic autoimmune disease — according to recognised international classification guidelines.
- People whose SLE has not responded well enough to steroid treatments and at least 2 immunosuppressant therapies, one of which must be a biologic (a type of medication made from living cells), each used for at least 3 months. Poor response can include not responding, not responding enough, not sustaining a response, or being unable to tolerate the treatment (confirm with trial site).
- People whose SLE is currently active, shown by specific disease activity scores and at least one positive blood test confirming the SLE diagnosis.
- People with a specific form of SLE affecting the kidneys (called lupus nephritis) must have had a kidney biopsy within approximately 6 months before signing the consent form, showing a particular type and level of kidney involvement with less than 60% scarring in the kidney tissue (confirm with trial site).
- People who have signed and dated an ethics-approved consent form before joining the trial.
Who may not be able to join:
- People who are pregnant.
- People who are already participating in another clinical trial involving an investigational (unapproved/experimental) treatment.
- People who are unwilling or unable to attend the regular follow-up appointments needed to collect study information.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of of participants achieving Definition of Remission in Systemic Lupus Erythematosus (DORIS) at 6 months along with the 95% CI.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.